Friday, April 15, 2011 (Last Updated: 04/18/2011)
FRIDAY, April 15 (HealthDay News) -- A set of plasma biomarkers in people with melanoma may be useful in predicting which patients are at risk for metastasis, according to research published in the April 15 issue of Clinical Cancer Research.
Harriet M. Kluger, M.D., of the Yale Cancer Center in New Haven, Conn., and colleagues measured plasma proteins in 108 metastatic melanoma patients, and 108 matched patients with resected stage I or II disease, to study protein levels in the former group that could be used to monitor that patient population.
The researchers identified seven biomarkers, all of which were higher in the metastatic melanoma patients than in those with early-stage disease. Of the early-stage patients, 81 percent had no marker elevation, but elevation was seen in at least one marker in 69 percent of those with metastatic disease.
"Plasma markers, particularly when assessed in combination, can be used to monitor patients for disease recurrence and can compliment currently used lactate dehydrogenase and imaging studies; prospective validation is warranted," the authors write.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.